We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




10 Minute RT-PCR Point-of-Care System Detects Up To 32 Targets Per Sample

By LabMedica International staff writers
Posted on 21 Mar 2024
Print article
Image: The molecular POC system can run up to 32 targets at a time on a single sample in
Image: The molecular POC system can run up to 32 targets at a time on a single sample in

A 10-minute RT-PCR point-of-care (POC) system and respiratory panel are set to change the discussion on next-generation POC testing.

Autonomous Medical Devices Incorporated (AMDI, Santa Ana, CA, USA) is developing its Fast PCR System, a CLIA-waivable RT-PCR POC system that can detect up to 32 targets per sample in less than 10 minutes. The AMDI Fast PCR system is a compact, easy-to-use molecular point-of-care system that utilizes multiplexing capability specifically for CLIA-waived environments. It can run up to 32 targets at a time on a single sample in <10 minutes using a disposable disc without the need for a separate, offline sample preparation. At the core of the AMDI ultrafast system is the company’s Hyperbaric Heating (HBH) sample prep technology combined with its ultrafast PCR chemistry. The HBH technology eliminates the time constraints and costs associated with traditional sample preparation.

Combining HBH with AMDI’s ultrafast thermal cycling allows the test time to stay under 10 minutes regardless of the number of targets put on the test disc. The AMDI ultrafast system is designed to deliver highly sensitive, lab-quality results with the accessibility needed to address the testing needs of both the current and future pandemics. AMDI is also developing the first test panel for the Fast PCR system, targeting the detection of multiple respiratory viruses. The AMDI Respiratory Panel tests for the four most probable viruses that cause respiratory tract infections since the pandemic, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2.

"Our market research indicates that our technology, when combined with cloud connectivity, can revolutionize patient care in the CLIA Waived setting," said David Okrongly, CEO of AMDI.

Related Links:
AMDI

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.